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A 48-year-old man with a history of juvenile-onset diabetes mellitus,
hypertension and coronary artery disease was seen because of an occluded
ePTFE arteriovenous graft. Diabetes was first diagnosed at age 8, and
insulin therapy was begun at that time. He remained in good health
without major diabetic sequelae until 18 years ago at age 30, when he
began experiencing difficulty with his vision; retinopathy was detected and
he was treated with laser surgery.
One year later he developed high blood pressure and diabetic neurop-
athy, which resulted in a neuropathic foot ulcer approximately 14 years
ago. At that time, an elevated serum creatinine level of 1.6 mg/dl was first
detected. Eight years ago, he suffered a non-Q-wave myocardial infarction,
complicated by the development of congestive heart failure. His renal
function gradually deteriorated, culminating in initiation of hemodialysis 8
months prior to the present admission. An arteriovenous ePTFE graft was
placed at that time, although a right subclavian Quinton catheter was used
for the initial 2 weeks of dialysis. His albumin was 3.5 g/dl and hematocrit
32% after he received several units of blood. Erythropoietin treatment was
begun. A few days later he suffered a cardiac arrest while on dialysis; he
was rapidly and successfully resuscitated. He had had intermittent rapid
atrial fibrillation with a rapid ventricular response a day earlier; the
digoxin level was 1.6 ng!ml. Quinidine, metoprolol, and warfarin were
added to his regimen. His medical regimen at the time of the present
admission for revision of the arteriovenous graft included insulin, 10 units
NPH/8 units regular every morning, and 8 units NPHJ8 units regular every
evening; metoprolol, 25 mg orally twice daily; warfarin, 4 mg orally daily;
aspirin, 325 mg orally each day; polysaccharide-iron complex, 300 mg
orally each day; calcium carbonate, 500 mg orally three times daily;
calcitriol, 0,50 jrg orally each day; and erythropoietin, 5000 U 3 times!
week.
On physical examination the patient was resting comfortably. His blood
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pressure was 160/93 mm Hg; heart rate, 86 beats/mm; respirations were
non-labored; and he was afebrilc. His physical examination was significant
for the presence of bi-basilar crackles and trace pedal edema. His left
forearm ePTFE arteriovenous graft did not have a palpable thrill or
audible bruit.
Important laboratory values included: serum sodium, 143 mEq/liter;
chloride, 99 mEq/liter; potassium, 5.2 mEq/liter; bicarbonate, 27 mmol/
liter; glucose, 363 mg/dl; BUN, 76 mg/dl; creatinine, 6.1 mg!dl; prothrom-
bin time was 16.2 seconds (INR 1.7), and hematocrit, 33.6%.
The patient underwent a thrombectomy and revision of the venous
anastomosis with a "jump graft." His discharge medications were the same
as those at admission.
Discussion
DR. Viis P. SUKHATME (Chief Renal Division, Beth Israel
Hospital, and Associate Professor of Medicine, Harvard Medical
School, Boston, Massachusetts): This case illustrates an all too
common, unfortunate outcome of a graft vascular access: a
diabetic patient with vascular disease who receives a PTFE graft
because he is not a candidate for arteriovenous (AV) fistula
placement. Pathologic examination of the failed graft showed
thrombus as well as marked vascular stenosis at the venous
anastomosis. The focus of this discussion is to review the patho-
biology of graft stenosis and to explore the use of gene delivery for
the treatment of, and as a way of studying the basic pathogenetic
mechanisms of, this lesion.
The aging dialysis population is living longer, and many of these
patients have significant vascular disease. Thus we should re-focus
our attention on the problem of permanent vascular access. In
particular, this population often requires the placement of grafts
rather than the creation of native AV fistulas. In 1990, for
example, in patients on hemodialysis for longer than 3 months,
83% had vascular access established via grafts [1]. Moreover,
given the significantly higher incidence of thrombosis/stenosis in
grafts versus AV fistulas [2], 1 will limit my discussion to graft
pathology. Although thrombosis is often the final event that
necessitates medical or surgical intervention, I will focus on the
problem of vascular stenosis because the most common abnor-
mality thought to predispose to thrombosis is underlying stenosis,
either at the graft venous anastomosis or further downstream in
the subclavian or axillary veins. In fact, stenotic lesions are found
in as many as two-thirds of patients with PTFE grafts who have
surgical thrombectomy [3—6]. Screening studies using Doppler
ultrasound show a direct correlation between the percentage of
stenosis and short-term thrombotic events: lesions with less than
30% stenosis have low rates of thrombosis, whereas a stenosis
greater than 50% augurs a poor outcome for the majority of
patients [7].
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In an era of cost-cutting, a brief review of a few figures is
enlightening. What is the cost of placing new vascular access and
of vascular access revisions? With the increasing percentage of
prosthetic accesses being placed, and their significantly higher
failure rate as compared to native fistulas, Windus has estimated
the cost for access placement and treatment for complications in
the U.S. at close to half a billion dollars annually [81. Moreover,
this number is likely to double over the next 6 to 7 years.
What are the clinical risk factors for graft occlusion? The
patient presented today had diabetes. The probability of graft
failure in diabetic patients at 6 and 12 months post placement is
55% and 72%, respectively [9]; these numbers contrast with 29%
and 49% failure rates in nondiahetics. However, these different
outcomes have not been corroborated in several other studies [6,
10, 11]. Another potential risk factor is erythropoietin (EPO)
therapy [12, 131. Platelet function in patients with end-stage renal
disease receiving erythropoietin might be closer to normal than in
patients not so treated. This fact might account for the larger
percentage of failed grafts in this population [12, 13]. Factors that
lead to diminished flow or that activate coagulation (needle
placement complications, site compression, hypotension, high
hematocrit levels) also might be important. A low albumin level
certainly is a risk factor for unknown reasons; patients with
albumin < 3.0 g/liter carry a 2.7 times greater risk than do those
with levels > 3.0 glliter [2]. Whether high-flux dialysis contributes
to the increased risk of graft failure is unknown and is a topic that
deserves closer scrutiny. Also, the uremic environment is gener-
ally a protector of graft function. Patients previously on hemodi-
alysis who undergo transplantation often have relatively early
closure of their functioning graft. Today's patient was diabetic,
receiving EPO and an anti-platelet agent (aspirin), and intermit-
tently took dipyridamole and warfarin since placement of the
graft; he had a normal albumin level.
Pathology of the lesion
As I said, the location of the stenotic lesion in graft accesses
most often is at the venous anastomosis. The histology is remark-
ably stereotypic, as it was in this patient (Fig. 1, Table 1) [14, 151.
Swcdberg et al examined 5 failed PTFE grafts by light and
electron microscopy and by immunocytochemical methods [14].
All the venous segments exhibited significant intimal hyperplasia
with proliferation of vascular smooth muscle cells and deposition
of extracellular matrix (ECM), these two components forming the
neo-intima. The composition of the matrix varied with radial
location in the vein. Proteoglycan predominated in the superficial
intima, whereas collagen and elastin occurred in the deeper
intima. Important because of their absence or near absence were
macrophages, foam cells, and lymphocytes, as well as extracellular
lipid deposits. The luminal surface of the graft itself, sometimes
covered by a gelatinous material containing fibrin, usually was not
covered by endothelial cells. Of note, the absence of hemosiderin
from the lesions suggests that the luminal fibromuscular lesion
probably did not represent organization of an original thrombus.
Moreover, the uniform intimal gradients of actin, collagen, and
proteoglycan suggested to the investigators that a progressive
rather than episodic proliferative response was occurring in this
lesion. This uniform response supports the postulate that up-
stream release of a mitogen such as PDGF, and possibly shear-
induced intimal injury, were important stimulants of this response.
In a recent abstract, Lumsden et al suggested a role for
neovascularization in the venous neo-intimal hyperplastic lesions
of arteriovenous grafts [16]. Using a canine model, they noted
widespread neovascularization of the neo-intima by capillary-
sized vessels and pointed to microvessel proliferation as an
important pathologic feature of advanced human lesions as well.
These findings suggest that therapeutic interventions aimed at
inhibiting angiogenesis might provide additional strategies for
preventing graft occlusion. Unfortunately, details of the canine
model mentioned in the abstract and in a recent review [17, 18]
have not been published, and no other studies, descriptive or
interventional, are available.
Interestingly, this vascular access stenotic lesion is a prominent
feature of the pathology occurring in many other models of
vascular injury: arterial prosthetic grafts, saphenous vein bypass
grafts, coronary arteries of transplanted hearts, the vasculature of
a transplanted kidney with chronic rejection, the re-stenosis that
occurs following percutaneous transluminal coronary angioplasty
(PTCA), atherosclerosis, and carotid arteries following endarter-
ectomy (Table 2) [19, 20]. Thus, this distinctive lesion seemingly is
part of a stereotypic response of the vasculature to many forms of
injury. Not withstanding this statement, it is important that I
emphasize the differences between the venous stenotic hyperplas-
tic lesion and that seen in some of these other situations. Several
distinguishing features exist: lipid droplets and T-cells and mac-
rophages are present in atherosclerotic plaques, and the distinct
boundary between intima and media present in the arterial wall,
namely, the internal elastic lamina, is not present in the vein.
Thus, the venous stenotic hyperplastic pathology seen in vascular
access grafts is perhaps more correctly described as a hyperplastic
intimal/medial lesion. The "instigating agents" in the different
clinical conditions also can differ. It is likely that platelets and
initial thrombus formation (platelets and fibrin) play a much more
critical role in the development and progression of an atheroscle-
rotic plaque than they do in the venous stenotic pathology. In
models of injury to the vasculature in a transplanted organ,
immunologic mechanisms might be more important. In the re-
stenosis lesion following PTCA, the endothelium sustains marked
injury in the form of endothelial denudation as well as likely
"distention" injury to vascular smooth muscle cells residing in the
media. Moreover, significant differences might exist with regard to
the chronicity of the insult: in the graft lesion, there appears to be
a smooth, continuous proliferation of vascular smooth muscle
cells and of extracellular matrix deposition, whereas in the
restenosis model, the major increase in cell proliferation occurs
within the first few days following acute injury.
Can we find analogous situations outside the vessel wall (Table
2)? In particular, two tissue/organ systems come to mind. The
mesangial cell in the glomerulus is a microanatomic extension of
the vascular smooth muscle cell [21, 22]. Both share certain
immunohistochemical markers such as a-smooth muscle actin.
The mesangial cell can contract and converts to a so-called
"activated phenotype" under certain conditions, for example, in
inflammatory states [21, 22]. Both cell types proliferate in re-
sponse to similar mitogcns. Thus, models of glomerular injury in
which the mesangium expands, both by proliferation of mesangial
cells and by increased deposition of extracellular matrix, might
represent the glomerular counterpart of vascular myo-intimal
hyperplasia. Another analogous system, although less clearly so, is
a comparison of the Ito cell in the liver to the vascular smooth
muscle cell. The Ito cell, which resides beneath the endothelial
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Fig. 1. A. Light micrograph from the
anaslomotic region of the patient's failed arterio-
venous graft. The lumen of the venous outflow
tract is delineated by the asterisk. Recent blood
clot can be seen within the PTFE graft
surrounded on either side by proliferative
smooth muscle growth which lines the PTFE
graft (arrows). B. Higher magnification of
Figure 1A. Proliferative smooth muscle cells
from the adjacent venous wall can be seen
lining the PTFE graft surface (arrows). The
stenosed lumen (asterisk) has a recently formed
blood clot.
cell in the space of Disse between the endothelial cell and the
hepatocyte, is believed to be the critical cell that undergoes
transformation as part of a response to hepatic injury [23]. The
transformation of the Ito cell changes it morphologically; it loses
fat granules and converts to positivity for a-smooth muscle actin.
The cell not only proliferates but produces increased amounts of
extracellular matrix and is thought to be the major culprit in the
fibrotic process that often ensues after hepatic injury. In fact,
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Table 1. Pathology of lesion
Intimal hyperplasia—vascular smooth muscle cell proliferation
Increased extracellular matrix
Central: protcoglycan
Deeper: collagen and elastin
Absence of macrophages, foam cells, lymphocytes, extracellular lipids
Graft lumen: fibrin
Absence of hemosiderin
Neovascularization
Table 2. Intimal hyperplasia: a common pathology
Vessel wall
Arterial prosthetic grafts
Saphenous vein bypass grafts
Coronary arteries of transplanted hearts
Vasculature of transplanted kidney with chronic rejection
Restenosis following percutaneous transluminal coronary angioplasty
Atherosclerosis
Carotid arteries post endarterectomy
Outside vessel wall (potentially analogous situations)
Liver injury/fibrosis: Ito cell
Kidney mesangium: mesangial cell
Human
Descriptive studies
Clinical trials
Animal models
Canine AV graft
Others: balloon injury, wire loop, aortic vein interposition graft
Cell culture studies
Vascular smooth cell proliferation and migration
Extracellular matrix production
Organ explant, co-culture studies
Upstream events
Injury to vessel wall
Immune/inflammatory events
Hemodynamic factors
Downstream events
Vascular smooth muscle cell migration
Vascular smooth muscle cell proliferation
Extracellular matrix production
proteins such as PDGF, bFGF, and TGF are expressed in
common in models of liver, kidney, and vascular injury. This sort
of comparison, although not perfect, is certainly worthy of our
attention. Pharmacologic interventions that help in one model
could be useful in others.
Patho biology
I'd like to start with an overview of the types of investigations
aimed at uncovering the pathobiology of the stenotic lesion (Table
3). Human studies have analyzed pathologic specimens, but an
extensive series of immunohistochemical markers has not been
explored (for example, antibodies to adhesion molecules, or
cytokines). In addition, a limited number of clinical trials have
been undertaken in patients with AV grafts [24—26]. In the animal
studies, a canine model has been described [16—18] that appears
to duplicate the histology of the human disease fairly well, but
little has been published. A considerable body of literature does
exist, however, on animal vascular models of injury that produce
lesions in which the prominent feature is intimal hyperplasia.
Therapeutic maneuvers in the animal models of AV graft failure
have not been tried, but extensive interventions have been utilized
in related animal models. At the level of cell culture studies, a vast
literature exists on the factors that influence vascular smooth
muscle cell proliferation and migration, and a similar large group
of studies has examined the mechanisms of extracellular matrix
production, both by vascular smooth muscle cells and by cells that
are related to them. The advantage of cell culture experiments is
that they can be done rapidly and important initial information
can be obtained. Furthermore, these experiments act synergisti-
cally with information from in-situ or immunohistochemical anal-
yses in animal models and human studies of the pathologic
lesions. A major disadvantage of the in-vitro studies is that the
complex architecture in which the pathology develops in humans
is not present, in that influences of multiple cell types generally
are not accounted for, and it is difficult to extrapolate concentra-
tions of exogenously added growth factors to the in-vivo situation.
In the realm of "organ" culture or co-culture experiments, for
example, of endothelial cells and vascular smooth muscle cells,
almost no literature exists.
We turn now from model systems to pathogenetic mechanisms
(Table 4). It is convenient to think about a number of early
instigators (upstream events) that feed into three processes
(downstream events) common to all models of vascular injury in
which intimal hyperplasia is a prominent feature: these down-
stream events are first, the migration of vascular smooth muscle
cells into the intima; second, their proliferation; and third, the
production of extracellular matrix. These are the three critical
features of the pathologic lesion, and prevention of one or more
of these steps could be the focus of an interventional therapeutic
strategy.
A few additional thoughts: Why is there not an even more
profound hyperplastic response in a stenotic lesion? Or, what in a
normal vessel prevents or retards vascular smooth muscle cell
migration, proliferation, and/or extracellular matrix production? I
pose this question in part because in a mini-course that I give in
a Sunday school, I teach about thinking methodologies. A useful
strategy is to ask: Why is there not more of something, for
example, why is there not more crime on the streets, as a way of
trying to approach the question of how we can stop crime. By
analogy, therefore, it may be that something impedes these
processes as part of the pathophysiology. For example, is there a
certain rate of apoptosis in vascular smooth muscle cells that
normally occurs, and is this rate diminished, thus contributing to
the vascular pathology? Or are inhibitors of vascular smooth
muscle cell migration into the intima normally present? In
keeping with this line of reasoning, the resolution phase of the
Thy-i model of glomerulonephritis provides some interesting
clues. In this complement-dependent mesangiolysis model, a
hyperproliferative mesangial response is followed by deposition of
extracellular matrix and then, most importantly, a few weeks later
by essentially complete resolution. This sequence occurs when
only a single injection of anti-Thy-i is given [27, 28]. Recent
studies have indicated that apoptosis is a major mechanism by
which the number of mesangial cells decrease [29]. It also has
Table 3. Levels of investigation
Table 4. Pathogenetic mechanisms
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been suggested that the extracellular matrix resolves as a result of
production of molecules such as secreted protein, which is acidic
and rich in cysteine (SPARC), or osteonectin, which has a variety
of biologic effects [28], including inhibition of expression of
TGFI3, binding of PDGF, modulation of angiogenesis, and induc-
tion of expression of collagenase types I and IV. My point in
mentioning these studies is to suggest that there may be thera-
peutic interventions in which we want to increase apoptosis of
vascular smooth muscle cells or drive production of molecules
that "chew up" or dissolve matrix.
Collectively, studies in different model systems have led to the
delineation of three early events: (1) endothelial injury; (2)
immune/inflammatory responses; and (3) hemodynamic effects
[17]. How does one decide whether a given factor is of pathoge-
netic importance? The first suggestion for the importance of a
factor, whether it be a cytokine or a cell such as a platelet,
neutrophil, or macrophage, is to note its "expression" during the
development of the pathology. For example, evidence of "expres-
sion" either by in-situ hybridization, immunocytochemical analy-
sis, or simple histology (in the case of cells) is at least a first and
important indicator. Second, the ability of this "expression" to
correlate with either severity of the disease or to correlate in time
course with disease development is obviously of import. A third
criterion that would suggest the pathogenetic importance of a
factor is whether introduction of the factor (for example, overex-
pression of a cytokine) can reproduce either part or all of the
pathologic lesion. Finally, and perhaps most important, does
blockade of the action of the factor prevent all or part of the
pathology from developing? Various experimental approaches
can be utilized to block the effect of a (protein) factor in cell
culture or in vivo. These include antisense and antibody strategies
as well as dominant-negative and knockout methods. With regard
to cells, immunodepletion experiments in vivo, although harder to
perform, can be quite instructive.
For today's discussion of graft stenosis, I have given most
prominence to studies descriptive or interventional in an animal
AV graft model or in human AV grafts. The descriptive studies
have been mentioned earlier; interventional studies have largely
been carried out in other models of intimal hyperplasia. Perhaps
the model most often used is the balloon catheter arterial injury
model and its modifications. When a balloon is inflated and pulled
through a vessel, the endothelial layer can be denuded easily.
Also, the vessel distends at the time of the injury. Therefore, the
relevance of this model to the intimal hyperplasia that occurs at
graft anastomotic sites is not obvious. Another type of injury
involves stretching the vessel without denuding the endothelial
lining, the goal being to define what role vascular distention alone
plays. Interestingly, this type of injury increases medial smooth
muscle cell number, and in fact might be most relevant in
hypertensive disease. Another model of arterial injury, which
relies on denudation of the intimal layer by a nylon wire loop,
differs from the balloon injury model; endothelium is removed but
without vessel distention. Vein interposition grafts placed in the
arterial circuit perhaps mimic more closely AV prosthetic grafts in
that the lesions are in veins. Clearly of most relevance to today's
discussion would be results in animal models utilizing AV grafts.
Even in such studies, one should bear in mind certain caveats.
The choice of an animal in which to conduct studies is important.
Dogs, for example, re-endothelialize much more effectively than
do humans, so that a PTFE graft in a canine model shows
considerably more endothelialization than in a human [17].
Second, models typically are set up in a nonuremic environment.
In the absence of a renal failure model, extrapolation from such
models to humans requires caution. Third, the cost of large-
animal maintenance can become prohibitive. For all these rea-
sons, the efficacy of new therapies in humans rather than animals
should be evaluated as soon as the intervention is judged to be
safe in humans.
With these reservations in mind, I begin with a review of the
results of human and animal AV graft studies and analyses of
models of vascular injury in which an interventional strategy has
been directed at a "downstream" event. These studies have
attempted to decrease either the migration or proliferation of
vascular smooth muscle cells, or the production of extracellular
matrix, events common to the underlying pathology in all the
models. I also will focus on factors that meet the criteria of
importance I cited earlier.
We will look first at the so-called injury model [17] and will
examine the three general early events postulated to lead to
intimal hyperplasia. This model, based on observations in athero-
sclerotic plaques as well as in animal models of endothelial injury,
revealed that platelet-derived growth factor (PDGF) is a powerful
smooth muscle mitogen. PDGF released from adherent platelets
following a denudation injury to the endothelium could drive
vascular smooth muscle cell proliferation. PDGF is also a potent
chemotactic agent for vascular smooth muscle cells, and the
requirement for migration from media to intima therefore could
also be potentially satisfied. A polyclonal antibody to PDGF in
fact will abrogate some of the hyperplastic response in an animal
model, reducing the intimal cross-sectional area by approximately
40%. However, it will not prevent this response completely [30].
In vivo, this antibody inhibited migration but not proliferation.
One also can question whether the antibody itself could penetrate
into the tissue of interest and achieve a sufficient concentration to
have an effect.
Several concerns have been raised about this model, however.
A denuding injury to the endothelium produced by a wire loop
leads to platelet adherence and thrombus formation but not to
hyperplasia. Moreover, it is unclear whether the injury model is
relevant to the human neo-intimal hyperplastic lesion seen with
prosthetic grafts; there is minimal platelet and thrombus accumu-
lation within the hyperplastic lesions, and the hyperplastic lesions
tend to occur in grafts in which there is an endothelial lining above
the smooth muscle cells within the neo-intima and not where
there is not.
One could use the antibody study to argue that the initial injury
step is not critical and that platelet aggregation is not important,
but that the molecule PDGF is still a key player. In fact, PDGF
can be produced by endothelial cells, monocytes, and macro-
phages, as well as by vascular smooth muscle cells themselves.
Local levels of PDGF might be elevated due to upstream thrombi
forming at the puncture sites in the graft, and PDGF secretion by
endothelial cells might be increased due to turbulent flow. I
should note, however, that unused AV grafts develop stenotic
lesions as well. Given all this information on the biologic action of
PDGF and its site of production, as well as the PDGF antibody
data, PDGF is probably one of the mediators important in the
development of intimal hyperplasia.
Another key molecule is basic fibroblast growth factor (bFGF)
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[31]. This molecule can be produced by endothelial cells, mono-
cytes, macrophages, as well as smooth muscle cells, and even
though it is minimally secreted under normal circumstances, it is
released in response to cell injury. Basic FGF exerts a mitogenic
effect on vascular smooth muscle cells, and has powerful angio-
genic activity, perhaps via induction of vascular endothelial
growth factor (VEGF). Finally, blockade of bFGF's action in
culture and in vivo, using a polyclonal antibody, inhibits smooth
muscle cell proliferation in the rat carotid balloon injury model
[32]. This is a striking result, but intimal thickening was not
significantly abrogated in this study; smooth muscle cell migration
and excessive extracellular matrix production in fact were not
prevented in this model. There is an important lesson to be
learned here: one can dissociate the three processes: vascular
smooth muscle cell proliferation, migration, and extracellular
matrix production. The fact that the antibodies to bFGF could not
prevent the latter two events tells us that other important biologic
mediators are at work. Another approach also has been used to
"block" bFGF's action; a bFGF-saporin conjugate (saporin is a
ribosome-inactivating protein) administered in vivo blocked vas-
cular smooth muscle cell proliferation in a denuding injury model
[33].
With regard to extracellular matrix production, a large litera-
ture details the role of transforming growth factor /3 (TGF/3) [34].
This molecule can be produced by platelets, by smooth muscle
cells when they are activated by monocytes, and by macrophages.
It can both stimulate and inhibit smooth muscle cell proliferation
[35]. Studies of gene transfer of an active form of TGF/3 into
vessel walls reveal increased matrix formation.
Some issues remain unresolved in an explanation of how
intimal hyperplasia occurs despite the delineation of candidate
mediators in this injury theory. For example, whatever the initial
injury, the hyperplastic process continues for a long period, even
underneath an endothelium that was never denuded in the first
place. One could argue that the venous endothelium at an AV
graft anastomosis is subject to continuous microscopic endothelial
injury that accounts for progression of this lesion. Countering this
hypothesis is the absence of organized microthrombi in the
pathology. Or one could argue that hemodynamic factors provide
ongoing insults.
We now turn to the immune/inflammatory cell theory [17]. The
immunocytochemical data in atherosclerotic lesions show clearly
that a large number of macrophages and lymphocytes are present;
however, these cells are not as prominent in the intimal hyper-
plastic venous stenotic lesion. Nevertheless, these cells might play
a role intraluminally even without damaging the vascular wall. For
example, they might be sticking transiently to the endothelial cell
surface, thereby leading to cytokine production. The ability of
these cells to stick to endothelial cells via adhesion molecules in
fact might be regulated by other stimuli. In the case of patients on
dialysis, one could postulate that the presence of IL-i could
upregulate endothelial adhesion molecules. This theory is under-
mined by the fact that unused grafts can stenose as well.
Finally, we come to the hemodynamic response theory [17].
Factors of importance might include flow velocity (low and high),
wall shear stress (low and high), and mechanical compliance
mismatch [reviewed in Ref. 36]. All these factors have been
implicated in intimal hyperplasia in various models, and I will not
review them in detail here. Suffice it to say that (1) much work
needs to be done in AV graft models, (2) the use of altered (for
example, a tapered) graft configuration has not produced marked
improvement, and (3) hemodynamic factors might not be easily
manipulable since high flow rates are a prerequisite for adequate
dialysis. However, research on how signals from hemodynamic
factors can be transduced, and what molecules and fundamentally
what genes are regulated in an AV graft model, should be fruitful
avenues of investigation [37—39]. An important feature of the
hemodynamic theory is that it can cause injury on a long-term
basis and therefore can be important in the perpetuation of the
hyperplastic process. The high flow rates important for dialysis
often result in unstable flow, which can create stress within the
vessel wall; furthermore, a variety of biologic mediators, including
those that I have already mentioned, may be released. It is also
possible that the endothelium senses flow disturbances at the
venous anastomosis as a "low" shear, thus upregulating vasoactive
and cell adhesion molecules [40—42].
Prevention
I shall focus on prevention of stenosis and thrombosis, rather
than on the treatment of a failed or failing graft. First, a few points
of general philosophy.
What are the pros and cons of focusing therapy on the upstream
versus the downstream events? The advantage of intervening in an
upstream event is that the results are likely to be more specific,
since the initiating factors may be quite different in the athero-
sclerotic process versus the graft vascular stenotic process. The
advantage of focusing on downstream events, namely, migration
and proliferation of vascular smooth muscle cells and extracellular
matrix production, is that we understand quite a bit about these
processes based on cell culture analyses, as well as on diverse
in-vivo models, so we can design rational therapies. These thera-
pies, however, can cause systemic toxicity; for example, a cytotoxic
therapy for vascular smooth muscle cells might affect other cells.
However, some of these therapies could be localized, for example,
through the delivery of agents by regional gene therapy, or via
activation of cytotoxic agents by enzymes that are produced locally
with the genes encoding those enzymes delivered in a gene
therapy protocol. The use of local ionizing radiation or of
antisense oligonucleotides again delivered locally constitutes
other modalities that might affect the proliferative state of the
vascular smooth muscle cell and yet minimize systemic toxicity.
Given the diversity of factors, both generative as well as
progressive, that lead to the lesion, considerable redundancy
obviously exists in the system. Redundancy has major implications
for therapeutic intervention. In particular, to block vascular
smooth muscle cell proliferation, one can take lessons from the
biology of cancer and suggest the use of multiple drugs, especially
those that function in different ways in the cell cycle. The delivery
of these drugs, that is, the timing as to when they are given
following placement of a graft, may also be of importance. It will
be important to ascertain in an animal model when vascular
smooth muscle cell replication actually occurs, for example, is it
maximal in the first few days after graft placement, as it is
following balloon injury?
With regard to interventional studies, little experimental work
has focused specifically on anastomotic venous hyperplastic le-
sions in the AV graft models. This is a real pity. Thus, most of the
studies using pharmacologic manipulation as well as gene transfer
have been in other models of injury, largely, arterial injury with
endothelial denudation, bypass grafts, atherosclerosis, and a host
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of in-vitro cell culture models. Excellent recent reviews are
available, but the relevance to vascular graft pathology is unclear
[19, 20].
Clinical drug trials. Surprisingly, only a few drug trials aimed at
blocking vascular graft stenosis have been conducted in patients
with AV grafts. To assess the importance of anti-platelet therapy,
Sreedhara et al conducted a prospective, randomized, double-
blind study [24], Dipyridamole was beneficial with new ePTFE
grafts, whereas aspirin did not improve, and in fact worsened, the
risk of thrombosis. However, neither dipyridamole nor aspirin had
any beneficial effect in patients with prior thrombosis of ePTFE
grafts, although the number of patients enrolled was small. The
authors also note that erythropoietin was not being utilized
routinely in the population under study. A trial with ticlopidine,
100 mg twice daily for 12 weeks, in which 32% of the patients had
grafts and the remaining had external shunts, gave a twofold
reduction in thrombosis, but a breakdown according to access type
was not given, nor was any attempt made to evaluate intimal
hyperplasia [25]. Diskin and coworkers used fish oil (EPA) in 7
patients with AV grafts [26]. Although the data on the extent of
stenosis were encouraging, conclusions were difficult to draw
because of the small study size. Moreover, no difference in graft
survival was noted at 6 months.
I would like to make a plea for more clinical work in our dialysis
patients with AV grafts, especially in the diabetic patients at
highest risk. Other approaches to prevention, including the use of
modified grafts such as tapered grafts, also have been considered
and will not be reviewed here. Unfortunately, no improvements
have resulted in the last decade. Other improvements through the
generation of novel substrates have not occurred, although some
approaches are promising [43—46].
Gene therapy. I wish now to turn to gene therapy as a possible
therapeutic modality. Gene therapy has not yet been employed
either in animal models or in humans for the prevention or
treatment of venous stenosis in grafts. To appreciate the difficul-
ties in the use of this type of therapy, a detour is in order. First, I
will discuss the general considerations that go into devising any
gene therapy protocol and outline currently available methods.
Second, I will discuss disease-specific considerations by relating
these general issues to the problem of vascular stenosis.
Somatic cell gene therapy, in contrast to germ-line therapy (not
relevant for today's discussion) is classified as either in vivo or ex
vivo. In the in-vivo form of gene delivery, the gene is carried in an
appropriate virus or is introduced by nonviral means. In ex-vivo
gene delivery, cells derived either from the patient or from other
sources are first genetically modified outside the body and subse-
quently re-introduced into the body.
Three major considerations go into any gene therapy protocol.
The first is delivery, the ability to introduce the appropriate gene
into specific cells and tissues. What is the efficiency with which the
gene can be introduced into these cells? That is, what fraction of
cells in a given tissue or organ will receive the gene? Is this
number 50% to 100%, 1% to 10%, or 0.001% to 0.1%? Classifi-
cation according to these three categories has biologic signifi-
cance. Clearly, replacement of an intracellularly acting protein,
for example, a tumor-suppressor transcription factor to block cell
proliferation, would require introduction into essentially 100% of
target cells. (An exception to this statement would occur if a
"bystander effect" exists, as has been postulated for the herpes
simplex virus thymidine kinase gene therapy effects). A 1% to
10% efficiency might suffice if the protein functions extracellu-
larly, that is, in a paracrine fashion. Finally, only a very small
fraction of target organ cells might need to be transduced to
stimulate an immune-mediated reaction. Moreover, in making
these assertions, it is critical that we ascertain whether the gene
therapy acts in a replacement capacity, that is, to supply a missing
factor, or whether it is aimed at countering the action of an
existing molecule (protein). These two considerations will deter-
mine the protein levels required to produce the desired biologic
effect and, in turn, will set lower limits on the required efficiency
of delivery. Another delivery issue related to the method under
consideration is whether non-replicating cells can be transduced;
retroviral vectors need a proliferating cell population for produc-
tive infection.
A second key consideration in gene therapy relates to expres-
sion. Can the exogenous gene be transcribed and the protein
expressed in the target tissue at a level high enough to achieve the
desired biologic effect? Can we regulate gene expression in the
target tissue? Can tissue specificity of expression be achieved, for
example, by incorporation of cis-regulatory elements in the trans-
ducing vector? And, last but not least, how long does expression
persist in the delivered cells or tissue?
Safely is the third critical consideration in any gene therapy
protocol. Is carcinogenesis likely? If delivery and expression are
relatively "promiscuous," that is, if they affect tissues that are not
the intended target, what deleterious effects might be expected in
the short run or in the long run?
The answers to these questions will depend on the application
in mind, for example, the severity of the disease, the time frame
over which it evolves, and the need for long-term versus short-
term expression, the type and location of target cells and tissues,
the vector used, and the gene being delivered. We now turn to a
summary of several methods used for delivering genes, and their
success in delivering genes to vasculature.
Several retroviral vectors have been designed for the transfer of
genes into mammalian cells [47—49]. The retrovirus system is
ideally suited for many ex-vivo applications, because retroviruses
can stably transduce target cells with very high efficiency. "Pack-
aging" cell lines to produce replication-defective recombinant
viruses can generate viruses with an enormous host range. One of
the problems with retroviral gene transfer is that until recently
only relatively low titers of virus were achievable, 104106 infec-
tious units/ml. Titers of greater than io with a retrovirus con-
taining a vesicular stomatitis virus (VSV) glycoprotein have now
been described [50]. Another notable point, an advantage or a
disadvantage depending on the application in question, is that in
order for target cells to be productively infected, that is, for
pro-viral integration to be achieved, cells have to undergo mitosis.
This feature might be an advantage for the prevention of vascular
stenosis, as dividing intimal vascular smooth muscle cells are a key
feature of the pathology. However, this feature can be exploited
only if the retrovirus can reach the vascular smooth muscle cells.
The major advantage of retroviral transfer is that one can achieve
stable expression which, in principle, can last for months to years.
Retroviral vectors have been used to transfer genes into vascula-
ture in vivo, but low efficiency is the norm (0.1% to 1%) [51].
The Nables have used retroviruses ex vivo and implanted
genetically engineered endothelial cells into a denuded porcine
iliofemoral artery [52]. Others have seeded endothelial cells into
canine prosthetic grafts [53], and vascular smooth muscle cells
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have been implanted on denuded arteries [54, 55]. Thus, geneti-
cally altered endothelial and/or vascular smooth muscle cells
might be suitable for delivering therapeutic genes to a graft site.
Adenovirus-based vectors have been of particular interest for
in-vivo gene therapy. High titers of the virus, greater than 1010
plaque-forming units/ml, are easily achievable, The virus has a
broad tissue-host range, and cells need not be replicating for
infection to occur. Indeed, adenoviruses can transduce many
terminally differentiated cell types, including hepatocytes, skeletal
muscle, endothelium, glia, neurons, pulmonary epithelium, and
synovial lining cells [56—63]. Finally, the adenovirus vector is
thought to be relatively safe, and the adenoviral genome is
maintained episomally in the target cell. Typically, the adenovi-
rally delivered gene is expressed for a period of a few weeks to
months. Unfortunately, the factors that determine this length of
time are unknown, although host immunity is likely to be involved.
Finally, cis-regulatory elements can be incorporated into the
vector, and these elements do function in the context of the
adenoviral genome.
Adenoviral vectors have certain disadvantages: the generation
of recombinants is somewhat tedious; the production of viral stock
is fairly labor intensive; there is a size constraint on the gene being
delivered; and adenovirus infection can lead to inflammation.
Finally, the mounting of an immune response, especially if repeat
therapy is required, threathens to limit the effectiveness of
adenoviral therapy, although different serotypes could be used to
circumvent the problem.
Adenoviral gene transfer into endothelial cells of a non-injured
vessel and into vascular smooth muscle cells (in an injury model)
is very efficient; approximate numbers range from 10% to close to
100% (in endothelial cells) and success requires occlusion of
blood flow for about 20 minutes [61, 64, 65]. The use of polox-
amers, a class of biocompatible polyols, to increase effective
adenoviral concentration could diminish this time requirement
[66]. A hybrid viral/non-viral vector system based on the HVJ
virus has had some success in the delivery of genes and oligonu-
cleotides to the vessel wall [67]; gene expression can last for a few
weeks with this system.
Perhaps the best studied of the "non-viral" approaches to gene
delivery include adenovirus-ligand DNA conjugates, lipofection,
and direct injection of DNA [47, 49, 68]. These methods are suited
to in-vivo applications of gene therapy, but use of these methods
is limited because they provide only transient gene expression.
Thus, their application might be limited to situations in which
intervention over days or weeks is all that is desired. Alternatively,
repeat therapy may be required. Of note, direct injection of DNA
might produce long-term expression, but so far success has been
limited primarily to cardiac and skeletal muscle cells and even
then only a few cells in the target organ are affected. A second
problem with these methods is low transduction efficiency. Using
liposomes and plasmid DNA to place genes into the vasculature
yields results similar to those obtained using retroviruses, very low
efficiency ( 0.1% to 1%). But this approach still might be useful
for applications in which an absent gene product is being supplied,
for example, production of local VEGF in occlusive disease [69].
How might gene therapy for vascular stenosis work (Table 5)?
I suggest that a primary goal should be to inhibit the migration
and proliferation of vascular smooth muscle cells and the produc-
tion of extracellular matrix. Suitable target molecules would be
PDGF, bFGF, and TGFp. One approach would be to use
Table 5. Gene therapy for venous stenosis
Target molecules/actions
VCAM: cell adhesion
NOS: vasodilation
PDGF: migration, proliferation
bFGF: proliferation, angiogenesis
TGF-: fibrosis
"Cell cycle" genes, e.g., Rb, HSV-TK, myc: proliferation
VEGF: angiogenesis
Approaches
Dominant negative receptor constructs (soluble, transmembrane)
Chimeric toxins
Antisense oligos
Target cells
Endothelial cells (EC)
Vascular smooth muscle cells (VSMC)
Caveats
Focus on upstream versus downstream events
Diversity of factors, redundancy
Delivery
Location of lesion is circumscribed
Lesion is accessible
Blood flow can be interrupted for short periods
Vein is a thin vessel—application from inside/outside
Vein is normal at time of AV graft placement
Cell type needed to be transduced (EC versus VSMC) depends on
gene to be delivered
Expression
Long duration likely required
Safety
Chronic non-lethal disease
dominant negative receptor constructs (for example, soluble or
transmembrane receptor constructs) transduced into either endo-
thelial cells or vascular smooth muscle cells. Targeting endothelial
cells may well be adequate for the "soluble" constructs. Another
strategy would be to use chimeric toxins, such as bFGF-saporin or
bFGF-diphtheria toxin moieties, which would bind to their re-
spective receptors on vascular smooth muscle cells. Another
possibility is to deliver antisense oligonucleotides to vascular
smooth muscle cells; for example, the oligonucleotides could be
directed against cell cycle genes. Intracellular antiproliferative
therapies necessitating gene transfer into a substantial number of
vascular smooth muscle cells also are worthy of consideration.
Another idea would be to utilize a drug-activating strategy, that is,
delivery of a gene, the product of which activates an orally
ingested drug at the site of gene delivery; this is a speculative but
appealing approach. Genes with products that diminish local
vasoconstriction or thrombosis or that alter immune/inflammatory
cell adhesion (for example, by expression of a soluble receptor by
endothelial cells) or angiogenesis are also logical candidates for
delivery into endothelial cells. These genes might require only a
small number of transduced cells, perhaps only <10%, to achieve
biologic efficacy.
How do issues of delivery, expression, and safety relate to the
problem of gene transfer for the graft venous stenotic lesion such
as that seen in our patient (Table 5)? Regarding delivery, note
that: (1) the location of the lesion is circumscribed and accessible;
(2) stoppage of blood flow for short periods will not destroy the
graft or be detrimental to the patient (heparin could be used
during the time of gene transfer); (3) the vein is a thin vessel—
application from both inside or outside can be considered; (4) at
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the time of placement of an AV graft, the vein is normal in
structure (unlike the situation of preventing restenosis post PTCA
in an atherosclerotic vessel); and (5) efficient transduction of
vascular smooth muscle cells in non-injured veins has not been
achieved. Expression of the exogenous gene, that is, transcription
and protein production, for long periods may be required, typi-
cally months or even years. Therefore, administration must be
repeated or a modality of gene transfer must be used that will lead
to long-term expression following single gene transfer therapy.
This issue is not trivial; indeed, it is perhaps the most serious
problem in any sort of gene therapy directed at a chronic process.
However, it is not obvious that chronic therapy will be needed; it
is conceivable that by attaining the appropriate balance between
the local effects of cytokines and delivering a gene for a relatively
short period, the process itself might be arrested permanently.
Safety must be considered. Clearly vascular stenosis is not an
immediate life-threatening problem; therefore, delivery of the
gene to other organs is of major concern. It is possible that with
the use of appropriately designed double-lumen catheters for
delivery, this risk could be minimized significantly. Moreover,
appropriate cell-type-specific promoters might be utilized to
ensure that expression occurs only in vascular endothelial cells or
in smooth muscle cells. Finally, there is also the tricky question of
whether the mechanical delivery method itself or the vector being
used will cause endothelial injury, either directly or as part of an
immune response.
Direct gene transfer methods into vasculature have already
taught us a great deal about the function of a variety of molecules.
First, I should mention that no work has been done, even with
marker genes, in an animal AV graft model. However, several
genes have been transferred into the vessel wall in several other
models. Using the HVJ liposome method mentioned earlier,
Morishita and colleagues introduced the gene for angiotensin-
converting enzyme (ACE) and noted increased vascular hypertro-
phy [70]. A nitric oxide synthase gene introduced into a balloon-
injured rat carotid artery reduced intimal thickening [67]. A
PDGF-B gene induced intimal hyperplasia [71]. A secreted mu-
tant of acidic FGF expanded the intima and increased intimal
angiogenesis [72], and the active TGFJ31 gene increased collagen
synthesis in the intima and media [73]. All these genes stimulated
vascular cell proliferation in vivo but clearly exerted different
effects on angiogenesis and matrix formation. Therefore, a com-
bination of the action of these genes is likely to be responsible for
the overall pathology. These data also suggest that multiple drugs,
agents that inhibit the action of one or more of those factors,
might be needed to block these various pathways. Strategies
aimed at blocking downstream events, such as vascular smooth
cell proliferation, also have been tried. These approaches include
the use of recombinant chimeric toxins [74—76], antisense oligo-
nucleotides [77—831, and particular gene transfer methods. Re-
garding the last of these, a herpesvirus thymidine kinase (TK)
gene in an adenoviral vector was introduced into smooth muscle
cells following balloon injury [84, 85]. Thymidine kinase converts
ganciclovir, a nucleoside analogue, into an active form; this
phosphorylated ganciclovir induces DNA chain termination in
dividing cells. The cells then die, Nearby cells also can be inhibited
by the toxic metabolite. A course of ganciclovir reduced intima-
to-media area ratios by approximately 50% three weeks after
balloon injury as compared to untreated controls [84]. Also, a
reduction in initial proliferation of about 40% was observed in the
HSVTK-ganciclovir-treated animals approximately 7 days follow-
ing gene transfer. Significant toxicities were not observed in
treated arteries or systemic organs. Very recently, a study from the
Nabels' and the Leiden laboratories [861 has shown that the
retinoblastoma gene (Rb) also can be used. In their experiments,
expression of a non-phosphorylatable constitutively active form of
Rb was utilized. This cytostatic gene therapy was effective in
limiting intimal smooth muscle cell proliferation for at least 3
weeks after injury.
In summary, I am suggesting that these types of studies in the
balloon injury model should be undertaken in arteriovenous graft
models. The AV graft work is far behind the balloon injury model
work because descriptive characterization of the various factors
involved by in-situ hybridization or immunochemical analysis has
not taken place. Moreover, no work has been done in this model
with regard to interventional gene therapy strategies. We don't
know, for example, whether an adenovirus vector or a liposome
will transfer genes, to what cell type, with what efficiency, for what
duration of expression, etc., and these preliminary data need to
first be generated in a graft model. Ex vivo genetically engineered
endothelial cells can seed grafts and express a marker gene for at
least 5 weeks following implantation [53].
I hope the discussion today has stimulated interest in this
problem—a very important problem for us as nephrologists—and
one which I think may serve as a model system for the other
disease states in which intimal hyperplasia is a prominent feature.
I would like to end by suggesting that the types of reagents that
will be generated in the analysis of this problem also will be useful
for the study of analogous lesions in the liver and in the kidney,
providing a further impetus for investigation.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Although some-
what controversial, it has been proposed that the atherosclerotic
lesion is monoclonal in nature resembling benign neoplasia [87].
Is there any information on the clonality of the vascular smooth
muscle lesions of the graft stenosis? Also, regarding the expansion
of extracellular matrix in the lesion, is there a change in the types
of collagen or other matrix proteins compared with those nor-
mally expressed in the venous wall?
DR. SUKHATME: No study on monoclonality has been done. To
answer your second question, the only immunocytochemical stud-
ies are the ones that I have mentioned, and the issue you raise has
not been addressed.
DR. MADIAS: Do we know which isoforms of PDGF are
involved in the intimal lesions of vascular injury that you de-
scribed? Are the effects of PDGF on vascular smooth muscle
replication or migration isoform specific? Are these phenomena
accompanied by changes in the level or type of PDGF receptors?
DR. SUKI-IATME: No data are available on PDGF isoforms in
human graft stenotic lesions or in animal AV graft models. As you
know, PDGF is a homo/heterodimeric molecule that comes in
three forms: AA, AB, and BB. The two receptors, a and /3, show
distinct binding specificities for the three PDGF isoforms. The a
receptor binds all three PDGFs, whereas the /3 receptor binds
PDGF-BB only. In the balloon catheter injury model, PDGF-A
chain, but not the PDGF-B chain, and PDGF receptor a and f3
subunit mRNAs are transiently upregulated in intimal smooth
muscle cells. It is certainly going to be important to know which
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isoforms and receptors are expressed, when, and in what abun-
dance in graft stenosis. With regard to isoform and receptor
specificity, both a and /3 receptors mediate mitogenic effects in
fibroblasts, but only the 13 receptor stimulates fibroblast chemo-
taxis; the a receptor is inhibitory.
DR. JOHN T. HARRINGTON (Acting Dean, Tufts University School
of Medicine, Boston): Could you tell us what happens to endothe-
hal cells if they are put on PTFE in an in-vitro system? Will
endothelial cells creep along the graft, and if so, for what
distance? Has that been done?
DR. SUKHATME: I'm not sure the exact experiment you are
asking about has been done. However, there is a large body of
surgical literature on seeding PTFE grafts with endothehial cells,
then placing them in vivo as interposition grafts, with the hope of
improving graft patency. Parameters such as seeding density,
incubation time, precoating of the graft with different substrates,
and graft porosity have all been assessed. End points assessed are
the area of the graft covered by endothelial cells at different time
points and the origin of the endothehial cells in the graft, that is,
whether they are the seeded ones or have migrated in transmu-
rally. Also, migration rates of endothelial cells from the cut edges
of adjacent artery have been measured. In one study it was found
that in 5—7 cm length PTFE grafts, the endothelial cells located in
the middle of the graft were derived from the migration of
capillaries through the graft surface [88]. Moreover, in situations
where the porosity of the graft prevented capillary ingrowth, no
endothelial cells were present even at three months after surgery.
Finally, it should be pointed out that there is a considerable
difference in the rates of endothelialization depending on the
animal studied. Humans tend to be on the low end of the scale,
dogs are somewhat higher, and other animals are even higher.
These data have implications for animal species to be used in an
animal model, if it is to replicate what is seen in humans.
DR. HARRINOTON: What stops endothelial cells from migrating
along the graft in vivo? You mentioned that these grafts are not
endothelialized. How far precisely are the grafts endotheliahized?
DR. SUKHATME: It is not clear what stops endothelial cells from
migrating along the graft in vivo. I suspect that these cells
continue to migrate but at a rather slow pace. As I said earlier, the
distance of migration, even after several months, in the animal
models and certainly in humans is small, that is, a few centimeters.
A critical question I might add is whether it is important for graft
patency that grafts be endothelialized. In the region underneath
the endothelial cells, one gets the maximal amount of vascular
smooth muscle cell proliferation. Thus, the hypoplastic pathology
occurs largely where there are endothelial cells. Vascular smooth
cells do not seem to creep up into the graft if there are no
endothelial cells along the way.
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): I have two questions. First, could you elaborate on the
balance between matrix-inducing and matrix-resolving processes
in the vascular stenotic lesion—in particular what is known about
the role of the metalloproteinases in this lesion? Second, could
you comment on the information currently available on animal
models of vascular stenosis?
DR. SUKHATME: Metalloproteinases might be important in two
aspects of the stenosis problem. Initially, elaboration of these
enzymes by vascular smooth muscle cells (perhaps stimulated by
cytokines) allows these cells to both proliferate and migrate from
media to intima [89, 90]. Increased expression has been noted in
both a balloon injury rat carotid artery model and in human
atherosclerotic lesions [91, 92]. Later in the formation of the
stenotic lesion, or perhaps where maximal amounts of extracellu-
lar matrix are present, I shall speculate that proteolytic activity
actually might be diminished. Unfortunately, no data are available
in animal models of vascular stenosis.
DR. SINGH: As you have alluded to in your excellent talk, in the
Thy-i model, heightened PDGF and FGF activity is not sustained
throughout the period following the initial insult. Is this true for
the expression of these cytokines in the vascular stenotic lesion?
DR. SUKHATME: No studies addressing this tissue are available
either in human lesions or the canine AV model.
DR. RICHARD LAFAYETtE (Division of Nephrology, New England
Medical Center): While we await the development of gene therapy,
are there any antiproliferative agents currently available that
might interrupt vascular smooth muscle cell growth? Specifically,
converting enzyme inhibitors have been demonstrated to be
anti-mitogenic in different circumstances. Might they be of use in
preventing access dysfunction?
DR. SUKHATME: Many of the factors affecting proliferation of
vascular smooth muscle cells also influence other cell types, so
that systemic toxicity might be a major concern of any such
pharmacologic intervention. Let me focus on angiotensin II as you
have suggested. Angiotensin II increases vascular smooth muscle
cell proliferation and can cause hypertrophy of these cells as well.
A study on the use of an ACE inhibitor in the balloon injury
model showed efficacy [93]. However, two trials of ACE inhibitors
in post-angioplasty patients were disappointing. There has been
no study in patients with AV grafts.
DR. LAFAYETFE: In terms of the specific growth factors dis-
cussed today, can any pharmacologic agents or immune agents
block their actions?
DR. SUKHATME: In response to this question and perhaps the
previous one, it might be worth stepping back and noting that a
large number of agents can cause proliferation of vascular smooth
muscle cells. These include norepinephrine, angiotensin II, sero-
tonin, bradykinin, certain prostaglandins and leukotrienes, vaso-
pressin, PDGF, EGF, FGF, and TGF-f3. In this regard, one might
consider agents such as misoprostol (a synthetic PGE1 analogue),
ketanserin (a serotonin inhibitor), triazolopyrimidine (trapidil, a
coronary vasodilator), and heparin. Each of these agents de-
creases the proliferation of vascular smooth muscle cells, some of
them, in fact, in response to serum or PDGF [see references in
17].
What about agents that block the action of PDGF? Trapidil
competes for receptor binding with PDGF, and suramin, an
anticancer agent, blocks the effect of multiple growth factors
including PDGF, EGF, and TGF-f3. I also would like to add that
in addition to blocking the action of one or more of these growth
factors, it might be equally important to diminish their produc-
tion. For example, anti-platelet agents might diminish platelet
aggregation at the puncture site, thereby decreasing PDGF re-
lease.
DR. MADIAS: I would like to expand on Dr. Lafayette's question.
HMG CoA reductase inhibitors are known to suppress the
proliferation of various cells including vascular smooth muscle
cells independent of cholesterol availability [94]. Indeed, these
agents decrease the migration of cultured vascular smooth muscle
cells as well [95]. Physiologically relevant concentrations of a-
tocopherol inhibit the proliferation of vascular smooth muscle
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cells [96]. Hydrocortisone inhibits serum-stimulated vascular
smooth muscle proliferation [97]. Finally, clinically relevant con-
centrations of glucose promote growth, proliferation, and growth
factor gene expression in vascular smooth muscle cells [98, 99].
Have these concepts been explored regarding their potential
influence on the pathogenesis and course of vascular stenosis?
DR. SUKI-IATME: Those are excellent comments. There is a small
literature on the use of steroids in the balloon injury model;
methylprednisolone has had dramatic effects when given at the
time of injury. I would envisage that this sort of therapy might be
particularly advantageous in situations in which "the action" is
occurring over a discrete period, a few days to a few weeks, which
seems to be the case in the re-stenosis problem. In the problem at
hand today, chronic intervention might be required, and one
would have significant concerns about using long-term steroids. A
study in a model of hypercholesterolemic rabbits with endothelial
injury induced by balloon angioplasty showed significant reduc-
tion of intimal hyperplasia after treatment with lovastatin [100]. I
am not aware of any studies with vitamin E.
Recently, with regard to misoprostol, POE1 has been shown to
inhibit DNA synthesis in arterial smooth muscle cells stimulated
by PDGF. Heparin might work in multiple ways: by stimulating
endothelial cell growth, by inhibiting vascular smooth muscle cell
proliferation, and by binding bFGF. Finally, the possibility of
utilizing heparin fragments with minimal anticoagulant activity,
especially fragments that might be administered subcutaneously,
certainly warrants further investigation.
DR. ANDREW S. KJNG (Division of Nephrology, New England
Medical Center): It is well known that arteriovenous grafts can
become stenotic whether or not they are used. Does the dialysis
procedure per se accelerate this process? If it does, would you
speculate on what dialysis-related factors are involved?
DR. SUKHATME: Unfortunately, the answer to your question is
not known, since, in general, grafts are not put in until the patient
is fairly close to requiring dialysis. I would speculate that dialysis-
related factors might include injury at the needle puncture site,
subsequent compression causing platelet aggregation and release
of PDGF, and other growth factors downstream. In addition,
increased circulating levels of cytokines during dialysis might lead
to increased release of vascular smooth muscle cell mitogens by
endothelial cells.
DR. JULIA NEURINGER (Division of Nephrology, New England
Medical Center): Is the adenovirus delivered systemically, or is it
injected directly into the graft? Might you need to worry, for
example, about infectious sequelae in a transplant patient or a
patient who is eventually going to undergo transplantation and
immunosuppressive therapy?
DR. SuKakmIn: I would contemplate delivery into the graft
using a double balloon catheter. Essentially the virus could be
instilled in the central area, which could later be aspirated. It
doesn't mean that the virus will not go elsewhere; small amounts
are likely to go to the liver. Are there ways to minimize that
toxicity? One could use a promoter that was in the endothelial cell
as one way to limit toxicity.
Another tricky question arises regarding the mode of delivery:
as you inflate the balloons—distal and proximal—are you going to
cause injury there and increase the chances of developing a
stenotic lesion? We don't know the answer to this question.
I don't think you need to worry about infection sequelae. The
viruses being utilized are replication deficient.
DR. HARRINGTON: You mentioned earlier that the adenovirus is
better than the retrovirus in gene delivery. Specifically, why is the
adenovirus better than the retrovirus?
DR. SUKHATME: Retroviruses can only productively infect divid-
ing cells. Nobody understands the reasons why cell division is
required, but in a normal vein, the mitotic index is very low.
Adenoviruses can infect non-dividing cells. Second, retroviral
titers are low (106 to i09, with pseudotyped viruses) compared to
adenoviral titers; thus the latter are more useful for in-vivo
therapy.
DR. MADIA5: A certain segment of the hemodialysis population
appears to be particularly prone to access failure. These patients
are commonly older, diabetic, and have a history of vascular
disease. Beyond technical and circulatory factors, are there any
insights related to the biology of the vascular wall that might
account for such a propensity?
DR. SUKHATME: That is a tough question. My suspicion is that
there is a "genetic component" to the way a tissue, such as the
vasculature, responds to "injury"; for example, the amount of a
growth factor that is secreted may have a genetic predisposition. I
can't quantitate that any further.
DR. MAmAs: Internal mammary artery coronary bypass grafts
have a remarkably greater patency rate than do saphenous vein
grafts [101]. Can modern molecular biology provide an explana-
tion for this observation?
DR. SUTUtATME: I am not sure. The increased patency rate of an
internal mammary artery graft might be due to its ability to release
vasodilatory molecules such as prostacyclin and nitric oxide.
Others have speculated that this small artery with a thin intima is
nourished from the luminal side and not through the vasa
vasorum, as occurs in larger arteries, and that this feature may be
important.
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